pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

CSL Behring LLC

updated 2mo ago

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.

community read0 votes
pipeline
10
marketed
10
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(10)

pipeline depth10 products
Marketed: 10
10Marketed
Marketed
(coagulation factor VIII (human) + von willebrand factor complex (human))
Hemophilia A (Factor VIII Deficiency)
Marketed
C1 esterase inhibitor (human)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Marketed
Haegarda
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Marketed
Kcentra
Bleeding And Clotting Disorders
Marketed
albutrepenonacog alfa LA
Hemophilia B (Factor IX Deficiency)
Marketed
antihemophilic factor (recombinant), single chain
Hemophilia A (Factor VIII Deficiency)
Marketed
cytomegalovirus immune globulin (human)
Cytomegalovirus (HHV-5) Infections
Marketed
etranacogene dezaparvovec
Hemophilia B (Factor IX Deficiency)
Marketed
factor XIII (human)
Fibrin Stabilizing Factor Deficiency (Factor XIII Deficie…
Marketed
garadacimab
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view CSL Behring LLC jobs →

News

  • Chiesi to buy KalVista in $1.9B deal for rare disease drug
    The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
    biopharma_dive · 3mo ago
  • Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
    The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.
    biopharma_dive · 3mo ago
identifiers
source
globaldata
top tags
Immunology2Infectious Disease1
mentioned in
2news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?